Across TCGA pan-cancer cohorts, BCL9L RNA is linked to patient survival in 30 of 34 cancer types, making it the most broadly survival-associated BCL9L data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher BCL9L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL9L expression acts as an unfavorable survival marker, although some lineages such as UCS and KIRC show a favorable association.

BLCA, UCS, and PAAD are the cancer types where BCL9L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.233	0.647	.002	47	view →
UCS	DFS	Median	IV	0.952	0.367	.001	46	view →
PAAD	OS	Quartile	All	0.452	0.800	<.001	44	view →
KIRC	DFS	Median	All	0.871	0.719	.001	38	view →
UVM	DFS	Median	All	0.449	0.732	.002	37	view →
LUAD	OS	Quartile	All	0.304	0.585	.001	25	view →
LIHC	OS	Tertile	All	0.679	0.840	.006	22	view →
CESC	DFS	Tertile	All	0.765	0.878	.002	22	view →
BRCA	OS	Quartile	II,III,IV	0.864	0.929	.002	18	view →
KIRP	OS	Median	IV	0.041	0.524	.013	15	view →
LUSC	DFS	Median	IV	0.134	0.827	.014	12	view →
MESO	OS	Median	II,III,IV	0.353	0.693	.040	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 30 lineages.

Exploration

Same gene, other analysis: BCL9L tumor-vs-normal RNA expression · all BCL9L data types